English (UK)
Meting van glutamine en glutamaat met de YSI 2900 in de ontwikkeling van anti-kanker medicijnen
Anti-cancer drug development is an important component of modern pharmacological research. One target for these drugs is the conversion of glutamine to glutamate because glutamine is an important energy source for many different types of tumour cells.
Obviously in order to test the efficacy of such drugs on tumour cell lines it is vital to be able to accurately and reliably measure both glutamine and glutamate, alongside other media components such as glucose and lactate.
One recent study into the action of the potent glutaminase inhibitor CB-839 made full use of the YSI 2900 Biochemical Analysers functionality. Glutaminase is a mitochondrial enzyme that converts glutamine to glutamate, the first step in glutamine utilisation.
In a study of antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806 using the YSI analyser it was found that CB-839 decreased activity in a manner that was associated with a marked decrease in glutamine consumption and glutamate production.
Alongside this there was a decrease in oxygen consumption and a number of tricarboxylic acid cycle intermediates. By comparison an oestrogen receptor–positive cell line, T47D, showed only modest effects on glutamine consumption and downstream metabolites when CB-839 was applied.
As CB-838 is orally bioavailable there are strong reasons for clinically investigating CB-839 in patients with glutamine-dependent tumours, as well as utilising the YSI Biochemical Analyser range in your oncological research.”
Labface.com August 2014
See the published Letter
Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Authors: Written by an international collaboration of Cancer Research Centres, and listed in published letter
Biochemie analyzer YSI 2900
Eenvoudig en snel naar nauwkeurige resultaten. Kostenefficiënte biochemie analyzer!